08/06/2026
๐ค Meet Our Expert at ๐๐ฆ๐ ๐ข ๐ถ๐ป ๐๐ผ๐ฐ๐๐ ๐๐ฟ๐ฒ๐ฎ๐๐ ๐๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐จ๐๐ ๐ฎ๐ฌ๐ฎ๐ฒ
We are honored to welcome ๐ฆ๐ช ๐๐ฟ. ๐ ๐ฎ๐ฟ๐ผ๐๐ป ๐๐น ๐๐ต๐ผ๐๐ฟ๐, Chief of Cancer Center, Chief Quality Officer and Oncologist/ Hematologist, American Hospital, Dubai, UAE
๐๐ฟ. ๐๐น ๐๐ต๐ผ๐๐ฟ๐ will share expert insights on:
๐ LBA 1 - Residual cancer burden (RCB) following neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk HER2+ early-stage breast cancer (eBC)
๐
Saturday, 13th June 2026
๐ Conrad, Dubai
๐ ๐ณ ๐๐ ๐ ๐๐ผ๐๐ฟ๐ from DHA
๐Click here to Register: https://bit.ly/ESMO_IN_FOCUS_BC_2026 (Link in Bio)
๐๏ธ Endorsed by Emirates Oncology Society (EOS) & Emirates Breast Cancer Working Group
๐ค Managed by ๐๐ผ๐ป๐๐ฒ๐ป๐ฒ๐ฟ๐